BSD2000 deep hyperthermia combined with chemotherapy improves quality of life in NSCLC patients

BSD Medical CorporationFeb 24 2010

BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) today announced that a study titled “BSD2000 Deep Hyperthermia Combined with Chemotherapy of PT regimen in Patients with Non-small Cell Lung Cancer” has been published in the current issue of The Chinese Journal of Lung Cancer (February 2010;13(2):132–135) by Yang, Zhao, and Wang. The article can be accessed at https://www.mdlinx.com/internalmdlinx/login.cfm (free online registration required). The clinical study, conducted at a prestigious hospital in China, involved 60 patients with non-small cell lung cancer (NSCLC) who were randomized to receive either chemotherapy (cisplatin and paclitaxel) combined with hyperthermia (delivered using the BSD-2000 Hyperthermia System) or chemotherapy without hyperthermia.

“BSD2000 Deep Hyperthermia Combined with Chemotherapy of PT regimen in Patients with Non-small Cell Lung Cancer”

The researchers compared the short-term tumor regression rate, side effects and quality of life improvement between the two groups. Efficacy was based on World Health Organization standards and included those patients who had a complete response>p<0.05). The main side effects were myelosuppression and gastrointestinal reactions, and there was no significant difference between the two groups for side effects (p>0.05).

The researchers concluded that “BSD2000 deep hyperthermia combined with chemotherapy in patients with NSCLC can significantly increase the efficacy, response rate and quality of life improvement and without increasing side effects compared to chemotherapy alone.”

Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world. Lung cancer is the fastest growing type of cancer in China and is the leading cause of death from cancer in men and the second leading cause of death from cancer in women in China. Non-small cell lung cancer is the most common type of lung cancer, comprising 80% of all cases.

With the assistance of Dalian Orientech, a privately owned company and its exclusive Chinese distributor, BSD obtained Chinese regulatory (SFDA) approval for the BSD-2000 in 2005, allowing Dalian Orientech to market and sell the system to hospitals throughout China. BSD has placed 17 BSD-2000 systems with Dalian Orientech customers in China.

Hyperthermia has been used in China for the treatment of cancer for many years, and several thousand simple hyperthermia cancer therapy systems are in place in China. The market objective for BSD in China is to continue to expand and upgrade the existing market for clinical hyperthermia equipment to the advanced features of the BSD-2000 Hyperthermia System.